nContact Surgical
Morrisville
About nContact Surgical
nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, nonconductive, continuous, bi-atrial lesions on the epicardium of a beating heart. To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $75.5M
- Funding stage: M&A
- Last round: Debt Financing (Nov 2014)
- Website: ncontactsurgical.com
- Phone: (919)466-9810
Industries & Categories
Health Care, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ncontact-surgical-3388723 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.